ReGen Biologics' CE-marks CMI (Collagen Meniscus Implant) implant:
This article was originally published in Clinica
ReGen Biologics has CE-marked its Collagen Meniscus Implant (CMI) system. Franklin Lakes, New Jersey-based ReGen is preparing to launch the CMI in Europe through its existing distribution partnership with SulzerMedica. The CMI system is used in treating tears of the meniscus of the knee and is a resorbable collagen scaffold designed to prevent or delay progressive degenerative changes in the knee joint by acting as surrogate meniscus material subsequent to a partial meniscectomy.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.